HC Wainwright & Co. Reiterates Buy on Cartesian Therapeutics, Maintains $25 Price Target
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $25 price target.
